Hyaluronic acid-coated and Olaparib-loaded PEI − PLGA nanoparticles for the targeted therapy of triple negative breast cancer / Huiping Hu, Yu Zhang, Wenting Ji, Hao Mei, Tingting Wu, Zihao He, Kaiping Wang, Chen Shi
Abstract Aim To prepare the hyaluronic acid-coated Olaparib-loaded PEI − PLGA nanoparticles (HA-Ola-PPNPs) and investigate their tumour-targeted anticancer effect. Methods The synthesis of HA-Ola-PPNPs was verified by DLS, TEM and SEM, followed was measured its cytotoxicity using CCK-8 assay. Confocal microscopy was used to observe the cellular uptake. Cell apoptosis was analysed by flow cytometry, biological SEM, and TEM. The expression of related proteins within the tumour site was investigated by immunostaining. Results The prepared HA-Ola-PPNPs showed a diameter of ∼160 nm with a negatively charged surface (−16.9 ± 2.7 mV) and sustained drug release behaviour. And the encapsulation efficiency of HA-Ola-PPNPs was 78.63 ± 5.29%. HA-Ola-PPNPs exhibited efficient in vitro and in vivo antitumor activities. HA-Ola-PPNPs induced cell apoptosis by upregulating Bax, Cytochrome C, and Caspase 3, downregulating Bcl-2 in breast cancer-bearing mice. Conclusions According to the results, the Ola-loaded and HA-coated PEI − PLGA nanoparticles could be considered as a powerful tumour-targeted drug delivery system for TNBC treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Journal of microencapsulation - 39(2022), 1, Seite 25-36 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hu, Huiping [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Hyaluronic acid |
|---|
| Umfang: |
1 Online-Ressource (12 p) |
|---|
| doi: |
10.1080/02652048.2021.2014586 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011131500 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011131500 | ||
| 003 | DE-627 | ||
| 005 | 20231109210022.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/02652048.2021.2014586 |2 doi | |
| 035 | |a (DE-627)KFL011131500 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/02652048.2021.2014586 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Hu, Huiping |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hyaluronic acid-coated and Olaparib-loaded PEI − PLGA nanoparticles for the targeted therapy of triple negative breast cancer |c Huiping Hu, Yu Zhang, Wenting Ji, Hao Mei, Tingting Wu, Zihao He, Kaiping Wang, Chen Shi |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (12 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Aim To prepare the hyaluronic acid-coated Olaparib-loaded PEI − PLGA nanoparticles (HA-Ola-PPNPs) and investigate their tumour-targeted anticancer effect. Methods The synthesis of HA-Ola-PPNPs was verified by DLS, TEM and SEM, followed was measured its cytotoxicity using CCK-8 assay. Confocal microscopy was used to observe the cellular uptake. Cell apoptosis was analysed by flow cytometry, biological SEM, and TEM. The expression of related proteins within the tumour site was investigated by immunostaining. Results The prepared HA-Ola-PPNPs showed a diameter of ∼160 nm with a negatively charged surface (−16.9 ± 2.7 mV) and sustained drug release behaviour. And the encapsulation efficiency of HA-Ola-PPNPs was 78.63 ± 5.29%. HA-Ola-PPNPs exhibited efficient in vitro and in vivo antitumor activities. HA-Ola-PPNPs induced cell apoptosis by upregulating Bax, Cytochrome C, and Caspase 3, downregulating Bcl-2 in breast cancer-bearing mice. Conclusions According to the results, the Ola-loaded and HA-coated PEI − PLGA nanoparticles could be considered as a powerful tumour-targeted drug delivery system for TNBC treatment | ||
| 653 | |a Targeted delivery system | ||
| 653 | |a PEI-PLGA nanoparticles | ||
| 653 | |a hyaluronic acid | ||
| 653 | |a Olaparib | ||
| 653 | |a TNBC | ||
| 700 | 1 | |a Zhang, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Wenting |e verfasserin |4 aut | |
| 700 | 1 | |a Mei, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Tingting |e verfasserin |4 aut | |
| 700 | 1 | |a He, Zihao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Kaiping |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Chen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of microencapsulation |d Abingdon : Taylor & Francis Group, 1984 |g 39(2022), 1, Seite 25-36 |h Online-Ressource |w (DE-627)KFL000005967 |w (DE-600)1491079-2 |w (DE-576)079719244 |x 1464-5246 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2022 |g number:1 |g pages:25-36 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/02652048.2021.2014586 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_05 | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2022 |e 1 |h 25-36 | ||